Skip to main content

Pharming Group N.V. announces today that the positive results of a Phase 3 clinical trial of the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in adult and adolescent patients with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency, have been published in Blood, the peer-reviewed international medical journal of the American Society of Hematology. Data from this study was previously announced on February 2, 2022.

“As we continue to seek a better understanding of APDS as a recently characterized rare disease, we remain committed to sharing our findings with researchers and doctors around the world."

- Anurag Relan MD, MPH | Chief Medical Officer
Cookies: This website uses cookies Check the cookies page for more information Accept Decline